The conversation is about adding a low dose of pyrilutamide to a hair loss treatment regimen. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
An increase in libido associated with the use of Pyri, and a discussion about how it may be working comparably to other hair loss treatments such as RU58841, Finasteride and Minoxidil.
A user's experience with the hair loss treatment Pyrilutamide KX-826, which has resulted in some side effects and shedding. The conversation also includes advice for baseline pictures and trying treatments for at least 6 months.
Considering treatments for hair loss, including Minoxidil, Finasteride, RU58841, Fluridil and Pyrilutamide. The user is weighing the risks of taking unapproved medication before it has been mass produced.
The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.
The conversation is about a potential new hair loss treatment called Breezula CB-03-01. Users are discussing updates on its development and sharing personal experiences with making or using it.
The conversation is about adding crushed bicalutamide or spironolactone to a topical mix with finasteride and minoxidil to suppress testosterone in hair follicles, similar to what RU58841 does. The user cannot obtain RU58841 in their country and is seeking advice on this alternative approach for hair loss treatment.
Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.
The user visited a trichologist due to ineffective topical finasteride treatment for hair loss. The trichologist recommended a new regimen including a two-month course of locoidon (cortisone 0.1%), followed by a solution containing minoxidil, hydrocortisone butirrate, estrone, progesterone, tocopherol acetate, trichosol, and transcutol.
The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.
OP uses 1mg finasteride, 2.5mg minoxidil, and 10mg biotin daily, along with a biotin, caffeine, and saw palmetto shampoo. OP noticed results after 5 months, with occasional heart palpitations from minoxidil.
The user used finasteride but stopped due to side effects, then used topical minoxidil for 13 months, and later added KX826/pyrilutamide for 8 months. They experienced shedding after starting pyrilutamide and use minoxidil and KX826 once daily.
The conversation is about comparing hair loss treatments Pyrilutamide (KX-826) and CB-03-01, discussing their cost, side effects, and effectiveness. The user questions whether to try CB-03-01, which is more expensive and potentially less effective, or switch to the cheaper and possibly better Pyrilutamide.
Be skeptical of claims about new baldness cures; current treatments like finasteride, dutasteride, and minoxidil remain the best options. New products like Breezula and PP405 lack compelling evidence and may not be available soon.
Hair loss treatment with latanoprost, minoxidil, and biotin showed progress. Latanoprost, a glaucoma drug, stimulates anagen phase and increases conversion of vellus hair to terminal hair.
Breezula is a potential hair loss treatment, but recent updates suggest it may not be as promising as initially thought. Some users express skepticism about its effectiveness based on past results.
Two Chinese suppliers provided legitimate RU58841, confirmed through a free drug testing service. The vendors were Shaanxi Greenyo Biotech and Lyphar, found on Made-in-China.
The post and conversation are about the high cost and skepticism surrounding pyrilutamide as a hair loss treatment, with comparisons to minoxidil, finasteride, and RU58841. The original poster defends pyrilutamide's effectiveness and criticizes others for dismissing it without proper understanding.
Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.
The conversation discusses the potential release of Winlevi in 2019 by Cassiopeia for hair loss treatment. It suggests a regimen combining minoxidil, Winlevi, Nizoral, and possibly dermarolling, with a comment mentioning Breezula as an alternative to finasteride without side effects.
The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.
The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.
A 30-year-old woman with androgenetic alopecia is considering bicalutamide to slow hair loss but is concerned about its impact on muscle growth due to its anti-androgen effects. Alternatives suggested include dutasteride, spironolactone, RU58841, and minoxidil, with concerns about bicalutamide's side effects.
A 35-year-old is considering Breezula, Pyrilutamide, or topical finasteride/dutasteride to protect against hair loss while on testosterone replacement therapy (TRT). They currently use finasteride, oral minoxidil, and dutasteride but experienced increased hair shedding with TRT.
The user healthydudenextdoor starting a new topical anti-androgen hair loss treatment, Pyrilutamide, and discussing their current regimen of finasteride and minoxidil.
The user experienced a slight decrease in hair shedding and scalp itch, and reduced sebum production using Pyrilutamide, but stopped due to chest pain, breathing difficulties, and heart issues. They felt normal a week after discontinuing and doubted FDA approval for the drug.
The user is considering switching from pyrilutamide to 0.025% topical finasteride due to concerns about effectiveness and past side effects from a scalp elixir. They aim to maintain hair until new treatments like breezula or GT00029 become available.